Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway

European Journal of Cancer

Volumn 53, Issue , 2016, Pages 171-180

  Van Maldegem, Annemiek M ^a   Bovée, Judith V M G ^a   Peterse, Elleke F P ^a   Hogendoorn, Pancras C W ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone tumour; Ewing sarcoma; IGF 1R; PARP pathway; Sarcoma; Soft tissue tumour

Indexed keywords

MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; SARCOMA, EWING; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 84952888928     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.009     Document Type: Review

References (99)

1. N. Esiashvili, M. Goodman, and R.B. Marcus Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data J Pediatr Hematol Oncol 30 6 2008 Jun 425 430
2. S.J. Cotterill, S. Ahrens, M. Paulussen, H.F. Jurgens, P.A. Voute, H. Gadner, and et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group J Clin Oncol 18 17 2000 Sep 3108 3114
3. C.D.M. Fletcher, J.A. Bridge, P.C. Hogendoorn, and F. Mertens WHO classification of tumours of soft tissue and bone 4th ed. 2015 306 309
4. M.C. Le Deley, O. Delattre, K.L. Schaefer, S.A. Burchill, G. Koehler, P.C. Hogendoorn, and et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial J Clin Oncol 28 12 2010 Apr 20 1982 1988
5. J.A. van Doorninck, L. Ji, B. Schaub, H. Shimada, M.R. Wing, M.D. Krailo, and et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group J Clin Oncol 28 12 2010 Apr 20 1989 1994
6. W. van der Ent, A.G. Jochemsen, A.F. Teunisse, S.F. Krens, K. Szuhai, H.P. Spaink, and et al. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53 J Pathol 233 4 2014 Aug 415 424
7. H.Y. Huang, P.B. Illei, Z. Zhao, M. Mazumdar, A.G. Huvos, J.H. Healey, and et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse J Clin Oncol 23 3 2005 Jan 20 548 558
8. C. Mackintosh, J.L. Ordonez, D.J. Garcia-Dominguez, V. Sevillano, A. Llombart-Bosch, K. Szuhai, and et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma Oncogene 31 10 2012 Mar 8 1287 1298
9. D.A. Solomon, J.S. Kim, J. Bondaruk, S.F. Shariat, Z.F. Wang, A.G. Elkahloun, and et al. Frequent truncating mutations of STAG2 in bladder cancer Nat Genet 45 12 2013 Dec 1428 1430
10. A.S. Brohl, D.A. Solomon, W. Chang, J. Wang, Y. Song, S. Sindiri, and et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation PLoS Genet 10 7 2014 Jul e1004475
11. B.D. Crompton, C. Stewart, A. Taylor-Weiner, G. Alexe, K.C. Kurek, M.L. Calicchio, and et al. The genomic landscape of pediatric Ewing sarcoma Cancer Discov 4 11 2014 Nov 1326 1341
12. F. Tirode, D. Surdez, X. Ma, M. Parker, M.C. Le Deley, A. Bahrami, and et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations Cancer Discov 4 11 2014 Nov 1342 1353
13. C. Rodriguez-Galindo Pharmacological management of Ewing sarcoma family of tumours Expert Opin Pharmacother 5 6 2004 Jun 1257 1270
14. D. LeRoith, and C.T. Roberts Jr. The insulin-like growth factor system and cancer Cancer Lett 195 2 2003 Jun 10 127 137
15. K. Siddle Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances Front Endocrinol (Lausanne) 3 2012 34
16. M.M. Chitnis, J.S. Yuen, A.S. Protheroe, M. Pollak, and V.M. Macaulay The type 1 insulin-like growth factor receptor pathway Clin Cancer Res 14 20 2008 Oct 15 6364 6370
17. H. Werner For debate: the pathophysiological significance of IGF-I receptor overexpression: new insights Pediatr Endocrinol Rev 7 1 2009 Sep 2 5
18. H. Werner Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer Oncogene 31 22 2012 May 31 2703 2714
19. O. Shevah, and Z. Laron Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report Growth Horm IGF Res 17 1 2007 Feb 54 57
20. C. D'Ambrosio, A. Ferber, M. Resnicoff, and R. Baserga A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis Cancer Res 56 17 1996 Sep 1 4013 4020
21. I. Burtscher, and G. Christofori The IGF/IGF-1 receptor signaling pathway as a potential target for cancer therapy Drug Resist Updat 2 1 1999 Feb 3 8
22. K. Bohlke, D.W. Cramer, D. Trichopoulos, and C.S. Mantzoros Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast Epidemiology 9 5 1998 Sep 570 573
23. P.F. Bruning, D.J. Van, J.M. Bonfrer, P.A. Van Noord, C.M. Korse, T.C. Linders, and et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer Int J Cancer 62 3 1995 Jul 28 266 270
24. S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, and et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 9113 1998 May 9 1393 1396
25. R. Kaaks, E. Lundin, S. Rinaldi, J. Manjer, C. Biessy, S. Soderberg, and et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden Cancer Causes Control 13 4 2002 May 307 316
26. R.A. Krajcik, N.D. Borofsky, S. Massardo, and N. Orentreich Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer Cancer Epidemiol Biomarkers Prev 11 12 2002 Dec 1566 1573
27. J.P. Peyrat, J. Bonneterre, B. Hecquet, P. Vennin, M.M. Louchez, C. Fournier, and et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer Eur J Cancer 29A 4 1993 492 497
28. M.S. Sandhu, D.B. Dunger, and E.L. Giovannucci Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer J Natl Cancer Inst 94 13 2002 Jul 3 972 980
29. P. Stattin, A. Bylund, S. Rinaldi, C. Biessy, H. Dechaud, U.H. Stenman, and et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study J Natl Cancer Inst 92 23 2000 Dec 6 1910 1917
30. P. Toniolo, P.F. Bruning, A. Akhmedkhanov, J.M. Bonfrer, K.L. Koenig, A. Lukanova, and et al. Serum insulin-like growth factor-I and breast cancer Int J Cancer 88 5 2000 Dec 1 828 832
31. H. Yu, F. Jin, X.O. Shu, B.D. Li, Q. Dai, J.R. Cheng, and et al. Insulin-like growth factors and breast cancer risk in Chinese women Cancer Epidemiol Biomarkers Prev 11 8 2002 Aug 705 712
32. D. Yee, R.E. Favoni, G.S. Lebovic, F. Lombana, D.R. Powell, C.P. Reynolds, and et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor J Clin Invest 86 6 1990 Dec 1806 1814
33. K. Scotlandi, S. Benini, M. Sarti, M. Serra, P.L. Lollini, D. Maurici, and et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target Cancer Res 56 20 1996 Oct 15 4570 4574
34. J.A. Toretsky, T. Kalebic, V. Blakesley, D. LeRoith, and L.J. Helman The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts J Biol Chem 272 49 1997 Dec 5 30822 30827
35. K. Scotlandi, M.C. Manara, M. Serra, M.T. Marino, S. Ventura, C. Garofalo, and et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival Eur J Cancer 47 8 2011 May 1258 1266
36. A. Prieur, F. Tirode, P. Cohen, and O. Delattre EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3 Mol Cell Biol 24 16 2004 Aug 7275 7283
37. L. Cironi, N. Riggi, P. Provero, N. Wolf, M.L. Suva, D. Suva, and et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells PLoS One 3 7 2008 e2634
38. M.C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P.L. Lollini, and et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma Clin Cancer Res 13 4 2007 Feb 15 1322 1330
39. C. Garofalo, C. Mancarella, A. Grilli, M.C. Manara, A. Astolfi, M.T. Marino, and et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma Mol Endocrinol 26 9 2012 Sep 1603 1616
40. A.T. Amaral, C. Garofalo, R. Frapolli, M.C. Manara, C. Mancarella, S. Uboldi, and et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents Clin Cancer Res 2015 Jan 21
41. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 7092 2006 May 25 424 430
42. R.J. Dowling, I. Topisirovic, B.D. Fonseca, and N. Sonenberg Dissecting the role of mTOR: lessons from mTOR inhibitors Biochim Biophys Acta 1804 3 2010 Mar 433 439
43. E. Hernando, E. Charytonowicz, M.E. Dudas, S. Menendez, I. Matushansky, J. Mills, and et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat Med 13 6 2007 Jun 748 753
44. J. Perez, A.V. Decouvelaere, T. Pointecouteau, D. Pissaloux, J.P. Michot, A. Besse, and et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model PLoS One 7 6 2012 e32458
45. M. Aoki, E. Blazek, and P.K. Vogt A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt Proc Natl Acad Sci U S A 98 1 2001 Jan 2 136 141
46. S. Mateo-Lozano, O.M. Tirado, and V. Notario Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation Oncogene 22 58 2003 Dec 18 9282 9287
47. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, and et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 3 2006 Feb 1 1500 1508
48. Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade Mol Cancer Ther 4 10 2005 Oct 1533 1540
49. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 13 2007 Mar 22 1932 1940
50. M. Patel, N.C. Gomez, A.W. McFadden, B.M. Moats-Staats, S. Wu, A. Rojas, and et al. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition Mol Cancer Res 12 11 2014 Nov 1610 1620
51. L. Cao, Y. Yu, S. Bilke, R.L. Walker, L.H. Mayeenuddin, D.O. Azorsa, and et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer Cancer Res 70 16 2010 Aug 15 6497 6508
52. R.T. Kurmasheva, L. Dudkin, C. Billups, L.V. Debelenko, C.L. Morton, and P.J. Houghton The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Res 69 19 2009 Oct 1 7662 7671
53. B. Schoeberl, E.A. Pace, J.B. Fitzgerald, B.D. Harms, L. Xu, L. Nie, and et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis Sci Signal 2 77 2009 ra31
54. J.B. Fitzgerald, B.W. Johnson, J. Baum, S. Adams, S. Iadevaia, J. Tang, and et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors Mol Cancer Ther 13 2 2014 Feb 410 425
55. A.S. Pappo, G. Vassal, J.J. Crowley, V. Bolejack, P.C. Hogendoorn, R. Chugh, and et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study Cancer 120 16 2014 Aug 15 2448 2456
56. H. Juergens, N.C. Daw, B. Geoerger, S. Ferrari, M. Villarroel, I. Aerts, and et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma J Clin Oncol 29 34 2011 Dec 1 4534 4540
57. D. Olmos, S. Postel-Vinay, L.R. Molife, S.H. Okuno, S.M. Schuetze, M.L. Paccagnella, and et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2 2010 Feb 129 135
58. S. Malempati, B. Weigel, A.M. Ingle, C.H. Ahern, J.M. Carroll, C.T. Roberts, and et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group J Clin Oncol 30 3 2012 Jan 20 256 262
59. P. Schoffski, D. Adkins, J.Y. Blay, T. Gil, A.D. Elias, P. Rutkowski, and et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours Eur J Cancer 49 15 2013 Oct 3219 3228
60. A.S. Pappo, S.R. Patel, J. Crowley, D.K. Reinke, K.P. Kuenkele, S.P. Chawla, and et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study J Clin Oncol 29 34 2011 Dec 1 4541 4547
61. W.D. Tap, G. Demetri, P. Barnette, J. Desai, P. Kavan, R. Tozer, and et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors J Clin Oncol 30 15 2012 May 20 1849 1856
62. A. Naing, P. Lorusso, S. Fu, D.S. Hong, P. Anderson, R.S. Benjamin, and et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors Clin Cancer Res 18 9 2012 May 1 2625 2631
63. J.C. Ame, C. Spenlehauer, and M.G. de The PARP superfamily Bioessays 26 8 2004 Aug 882 893
64. C. Underhill, M. Toulmonde, and H. Bonnefoi A review of PARP inhibitors: from bench to bedside Ann Oncol 22 2 2011 Feb 268 279
65. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, and et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 Jul 9 123 134
66. B. Lupo, and L. Trusolino Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited Biochim Biophys Acta 1846 1 2014 Aug 201 215
67. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, K.W. Lau, and et al. Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 7391 2012 Mar 29 570 575
68. J.C. Brenner, F.Y. Feng, S. Han, S. Patel, S.V. Goyal, L.M. Bou-Maroun, and et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma Cancer Res 72 7 2012 Apr 1 1608 1613
69. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, J.H. Doroshow, and et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors Cancer Res 72 21 2012 Nov 1 5588 5599
70. R.E. Norris, P.C. Adamson, V.T. Nguyen, and E. Fox Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors Pediatr Blood Cancer 61 1 2014 Jan 145 150
71. M.A. Smith, C.P. Reynolds, M.H. Kang, E.A. Kolb, R. Gorlick, H. Carol, and et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program Clin Cancer Res 21 4 2015 Feb 15 819 832
72. J.L. Ordonez, A.T. Amaral, A.M. Carcaboso, D. Herrero-Martin, C.G.-M. Del, V. Sevillano, and et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Oncotarget 6 22 2015 Aug 7 18875 18890
73. H.J. Lee, C. Yoon, B. Schmidt, dJ. Park, A.Y. Zhang, H.V. Erkizan, and et al. Combining PARP-1 inhibition and radiation in ewing sarcoma results in lethal DNA damage Mol Cancer Ther 12 11 2013 Nov 2591 2600
74. E. Choy, J.E. Butrynski, D.C. Harmon, J.A. Morgan, S. George, A.J. Wagner, and et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy BMC Cancer 14 2014 813
75. A. O'Neill, N. Shah, N. Zitomersky, M. Ladanyi, N. Shukla, A. Uren, and et al. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature Sarcoma 2013 2013 450478
76. J. Engel, L. Blanchet, U.F. Engelke, R.A. Wevers, and L.M. Buydens Towards the disease biomarker in an individual patient using statistical health monitoring PLoS One 9 4 2014 e92452
77. A.M. van Maldegem, P.C. Hogendoorn, and A.B. Hassan The clinical use of biomarkers as prognostic factors in Ewing sarcoma Clin Sarcoma Res 2 1 2012 7
78. C. Garofalo, M.C. Manara, G. Nicoletti, M.T. Marino, P.L. Lollini, A. Astolfi, and et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling Oncogene 30 24 2011 Jun 16 2730 2740
79. M.J. Wagner, and R.G. Maki Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer Front Oncol 3 2013 9
80. R.L. Ferris, E.M. Jaffee, and S. Ferrone Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 28 2010 Oct 1 4390 4399
81. W. Wang, A.K. Erbe, J.A. Hank, Z.S. Morris, and P.M. Sondel NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy Front Immunol 6 2015 368
82. F. Bibeau, E. Lopez-Crapez, F.F. Di, S. Thezenas, M. Ychou, F. Blanchard, and et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 7 2009 Mar 1 1122 1129
83. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 3 2002 Feb 1 754 758
84. A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, and et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer J Clin Oncol 26 11 2008 Apr 10 1789 1796
85. R.J. Taylor, S.L. Chan, A. Wood, C.J. Voskens, J.S. Wolf, W. Lin, and et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck Cancer Immunol Immunother 58 7 2009 Jul 997 1006
86. W.K. Weng, and R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 21 2003 Nov 1 3940 3947
87. L. Tentori, A. Muzi, A.S. Dorio, M. Scarsella, C. Leonetti, G.M. Shah, and et al. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent Curr Cancer Drug Targets 10 4 2010 Jun 368 383
88. T.J. Key, P.N. Appleby, G.K. Reeves, and A.W. Roddam Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies Lancet Oncol 11 6 2010 Jun 530 542
89. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 12 2008 Dec 915 928
90. P.P. Connell, K. Jayathilaka, D.J. Haraf, R.R. Weichselbaum, E.E. Vokes, and M.W. Lingen Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers Int J Oncol 28 5 2006 May 1113 1119
91. C.M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy Proc Natl Acad Sci U S A 105 52 2008 Dec 30 20810 20815
92. H. Maacke, K. Jost, S. Opitz, S. Miska, Y. Yuan, L. Hasselbach, and et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma Oncogene 19 23 2000 May 25 2791 2795
93. H. Maacke, S. Opitz, K. Jost, W. Hamdorf, W. Henning, S. Kruger, and et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer Int J Cancer 88 6 2000 Dec 15 907 913
94. L. Oplustilova, K. Wolanin, M. Mistrik, G. Korinkova, D. Simkova, J. Bouchal, and et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment Cell Cycle 11 20 2012 Oct 15 3837 3850
95. G.B. Qiao, Y.L. Wu, X.N. Yang, W.Z. Zhong, D. Xie, X.Y. Guan, and et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients Br J Cancer 93 1 2005 Jul 11 137 143
96. E. Raderschall, K. Stout, S. Freier, V. Suckow, S. Schweiger, and T. Haaf Elevated levels of Rad51 recombination protein in tumor cells Cancer Res 62 1 2002 Jan 1 219 225
97. T. Takenaka, I. Yoshino, H. Kouso, T. Ohba, T. Yohena, A. Osoegawa, and et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer Int J Cancer 121 4 2007 Aug 15 895 900
98. J. Flygare, S. Falt, J. Ottervald, J. Castro, A.L. Dackland, D. Hellgren, and et al. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis Exp Cell Res 268 1 2001 Aug 1 61 69
99. C. Richardson, J.M. Stark, M. Ommundsen, and M. Jasin Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability Oncogene 23 2 2004 Jan 15 546 553